Kangji Medical Holdings 관리

관리 기준 확인 4/4

Kangji Medical Holdings CEO는 Ming Zhong, Aug2004 에 임명되었습니다 의 임기는 20.25 년입니다. 총 연간 보상은 CN¥ 1.23M, 96.2% 로 구성됩니다. 96.2% 급여 및 3.8% 보너스(회사 주식 및 옵션 포함). 는 € 284.51M 가치에 해당하는 회사 주식의 33.78% 직접 소유합니다. 284.51M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 4.7 년입니다.

주요 정보

Ming Zhong

최고 경영자

CN¥1.2m

총 보상

CEO 급여 비율	96.2%
CEO 임기	20.3yrs
CEO 소유권	33.8%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	4.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ming Zhong 의 보수는 Kangji Medical Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥534m
Mar 31 2024	n/a	n/a	CN¥519m
Dec 31 2023	CN¥1m	CN¥1m	CN¥504m
Sep 30 2023	n/a	n/a	CN¥540m
Jun 30 2023	n/a	n/a	CN¥576m
Mar 31 2023	n/a	n/a	CN¥528m
Dec 31 2022	CN¥1m	CN¥1m	CN¥479m
Sep 30 2022	n/a	n/a	CN¥447m
Jun 30 2022	n/a	n/a	CN¥415m
Mar 31 2022	n/a	n/a	CN¥436m
Dec 31 2021	CN¥1m	CN¥990k	CN¥457m

보상 대 시장: Ming 의 총 보상 ($USD 170.18K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.44M ).

보상과 수익: Ming 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ming Zhong (48 yo)

20.3yrs

테뉴어

CN¥1,232,000

보상

Mr. Ming Zhong serves as Executive Director of Kangji Medical Holdings Limited since March 7, 2020 and Chief Executive Officer since August 24, 2004 and is its Executive Chairman since May 2024. He is main...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ming Zhong	Executive Chairman of the Board & CEO	20.3yrs	CN¥1.23m	33.78% € 284.5m
Yinguang Shentu	Vice GM & Executive Director	8yrs	CN¥1.03m	19.14% € 161.2m
Zixin Yin	Vice GM & Executive Director	4.7yrs	CN¥1.94m	데이터 없음
Yanyu Hu	Chief Financial Officer	1.2yrs	데이터 없음	데이터 없음
Jianyong Ju	Head of Domestic Sales & Marketing	3.8yrs	데이터 없음	데이터 없음
Siu Keung Wan	Company Secretary	2.5yrs	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

45.5yo

평균 연령

경험이 풍부한 관리: 50J 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ming Zhong	Executive Chairman of the Board & CEO	4.8yrs	CN¥1.23m	33.78% € 284.5m
Yinguang Shentu	Vice GM & Executive Director	4.7yrs	CN¥1.03m	19.14% € 161.2m
Zixin Yin	Vice GM & Executive Director	2.6yrs	CN¥1.94m	데이터 없음
Jian Guo	Independent Non-Executive Director	4.7yrs	CN¥102.00k	데이터 없음
Lydia Cai	Non-Executive Director	4.7yrs	데이터 없음	데이터 없음
Weibo Chen	Independent Non-Executive Director	4.7yrs	CN¥102.00k	데이터 없음
Feng Jiang	Independent Non-Executive Director	4.7yrs	CN¥102.00k	데이터 없음

4.7yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 이사회: 50J 의 이사회는 경험(평균 재직 기간 4.7 년)으로 간주됩니다.

Kangji Medical Holdings 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Kangji Medical Holdings Limited, Annual General Meeting, May 27, 2024

Kangji Medical Holdings Limited Announces CFO Changes

Less than half of directors are independent

Kangji Medical Holdings Limited Announces Executive Changes

Less than half of directors are independent

Kangji Medical Holdings Limited Appoints Frances Fang Chovanec as Executive Director

Recent updates

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

Kangji Medical Holdings Limited to Report First Half, 2024 Results on Aug 20, 2024

New minor risk - Share price stability

Kangji Medical Holdings Limited Approves Special Dividend for the Year Ended 31 December 2023, Payable on 18 July 2024

Upcoming dividend of CN¥1.40 per share

Full year 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.40 in FY 2022)

Kangji Medical Holdings Limited Proposes Special Dividend for the Year Ended December 31, 2023

New major risk - Dividend sustainability

Dividend of CN¥1.40 announced

Kangji Medical Holdings Limited, Annual General Meeting, May 27, 2024

New minor risk - Share price stability

Kangji Medical Holdings Limited Announces CFO Changes

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.13 in 1H 2022)

Kangji Medical Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Kangji Medical Holdings Limited Approves Payment of Final Dividend for the Year Ended December 31, 2022, Payment Date Is 10 July 2023

Full year 2022 earnings released

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 1H 2021)

Kangji Medical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021, Payment date is 08 July 2022

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.17 per share

Kangji Medical Holdings Limited Announces Executive Changes

Full year 2021 earnings released: EPS: CN¥0.37 (vs CN¥0.26 in FY 2020)

Less than half of directors are independent

Kangji Medical Holdings Limited to Report Fiscal Year 2021 Results on Mar 22, 2022

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.16 (vs CN¥0.12 in 1H 2020)

Investor sentiment improved over the past week

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.31 in FY 2019)

Kangji Medical Holdings Limited Proposes Final Dividend for the Year Ended December 31, 2020

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.31 in FY 2019)

Kangji Medical Holdings Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

Investor sentiment deteriorated over the past week

New 90-day low: €1.15

New 90-day low: €1.27

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day low: €1.50

Market pulls back on stock over the past week

New 90-day low: €2.06

Kangji Medical Holdings Limited Appoints Frances Fang Chovanec as Executive Director

First half earnings released

Earnings released

Kangji Medical Holdings Limited to Report First Half, 2020 Results on Aug 25, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령